MiMedx Group, Inc. announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a webcast and conference call with senior management at 4:30 p.m. Eastern Time to review the results.

MIMEDX marks the 15th anniversary of its flagship placental allograft products EPIFIX and AMNIOFIX, which have been featured in nearly 100 clinical and scientific publications including seven randomized controlled trials. The company positions these products as the industry's most studied placental allografts, used across multiple surgical specialties for wound care and surgical recovery applications.

MiMedx Group will report its third quarter 2025 financial results on October 29, 2025, with a webcast and conference call scheduled for 4:30 p.m. Eastern Time.

MiMedx Group will showcase its advanced wound care portfolio at the Symposium on Advanced Wound Care Fall meeting in Las Vegas, presenting six clinical and scientific posters focused on wound healing technologies and treatments.

MediWound has initiated a global Phase III trial to evaluate the efficacy and safety of its wound debridement therapy EscharEx for the treatment of venous leg ulcers. The trial aims to assess EscharEx's ability to effectively debride chronic wounds and prepare the wound bed for healing.

The chronic wound care market is expected to grow at a CAGR of 4.17% from 2024 to 2031, driven by the high prevalence of chronic diseases and advancements in wound care technologies. The market is segmented by product, application, end-user, and region, with North America leading due to its developed healthcare infrastructure.

The article highlights the benefits of placental allografts for wound care and surgical procedures, featuring two individuals who had successful recoveries using MIMEDX's products. The article is expected to increase awareness about the unique properties and growing clinical use of placental-derived products.

MIMEDX, a leader in wound care products, is showcasing its latest research and clinical evidence at the Symposium on Advanced Wound Care (SAWC) Fall meeting. The company is sponsoring a lunch symposium and a hands-on skills lab, and has seven accepted posters on various topics related to wound healing.

MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company’s Senior Vice President, Sales since August 2020.

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

Mizuho has decided to maintain its Buy rating of MiMedx Group (NASDAQ:MDXG) and raise its price target from $13.00 to $14.00. Shares of MiMedx Group are trading up 0.98% over the last 24 hours, at $8.24 per share. A move to $14.00 would account for a 69.9% increase from the current share price. About MiMedx Group MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include ...Full story available on Benzinga.com